Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned: ingredients and opioid-controlled nature are supported, but multiple manufacturing/testing process claims and DIY-manufacturing legality/dosing explanations are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Percocet contains two active ingredients: oxycodone and acetaminophen (paracetamol).
DESCRIPTION section: each tablet contains oxycodone hydrochloride and acetaminophen.
Percocet is a controlled prescription opioid combination product.
WARNINGS section: PERCOCET contains oxycodone, a Schedule II controlled substance; DESCRIPTION indicates oxycodone + acetaminophen.
Unsupported Statements
Combination tablet medicines like Percocet are made by making the drug substances to pharmaceutical specifications.
No manufacturing/specification-process content present in the provided label excerpts.
Combination tablet medicines like Percocet are made by blending the ingredients with other tablet-forming ingredients so the final dose is consistent in every pill.
No blending/dose-consistency manufacturing explanation present in the provided label excerpts.
Combination tablet medicines like Percocet are made by compressing into tablets.
No tablet-compression manufacturing description present in the provided label excerpts.
Combination tablet medicines like Percocet are made by coating, polishing, and packaging the tablets under controlled conditions, followed by quality testing.
No coating/polishing/packaging manufacturing description present in the provided label excerpts.
Manufacturers test finished tablets for drug identity (confirming the correct chemicals are present).
No QC testing/identity testing described in the provided label excerpts.
Manufacturers test finished tablets for strength and content uniformity (each tablet contains the right amount of oxycodone and acetaminophen).
No QC testing/strength/content uniformity described in the provided label excerpts.
Manufacturers test finished tablets for dissolution/performance (how the tablet breaks down and releases medicine).
No dissolution/performance testing described in the provided label excerpts.
Manufacturers test finished tablets for impurities and stability (contaminants and shelf-life).
No impurities/stability testing described in the provided label excerpts.
Attempting to manufacture Percocet yourself is dangerous and illegal in many places.
No statement about illegality of DIY manufacturing present in the provided label excerpts.
Attempting to manufacture Percocet yourself is dangerous because the exact dosing is hard to measure.
No label support for 'hard to measure' dosing rationale for DIY manufacturing in the provided excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
No evaluation of contraindications, boxed warnings, dosing and administration, or monitoring because those sections were not provided (WARNINGS header present but substantive content provided selectively; DOSAGE AND ADMINISTRATION provided as an empty excerpt).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims about DIY manufacturing are not supported by the provided label excerpts. Although overdose/toxicity risk from oxycodone/acetaminophen is supported generally, the unsupported claims include legality and dosing-measurement rationale, which could mislead in a way not directly addressed by the provided labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple manufacturing/QC and DIY-manufacturing claims are absent from the provided label excerpts and therefore unsupported.
Suggested Improvement
Restrict claims to on-label statements present in the provided label excerpts (e.g., ingredients, opioid Schedule II status, and overdose/toxicity descriptions) and remove or qualify manufacturing/testing-process and 'illegal in many places' statements unless supported by the supplied labeling.